Original Article

Naringenin inhibits pacemaking activity in interstitial cells of Cajal from murine small intestine

Hyun Jung Kim, Byung Joo Kim*

Division of Longevity and Biofunctional Medicine, Pusan National University School of Korean Medicine, Yangsan, Korea

A R T I C L E  I N F O

Article history:
Received 9 January 2017
Received in revised form
6 February 2017
Accepted 7 February 2017
Available online 16 February 2017

Keywords:
Ca²⁺-activated K⁺ channel
gastrointestinal tract
interstitial cells of Cajal
naringenin

A B S T R A C T

Background: Naringenin (NRG) is a common dietary polyphenolic constituent of fruits. NRG has diverse pharmacological activities, and is used in traditional medicine to treat various diseases including gastrointestinal (GI) disorders. Interstitial cells of Cajal (ICCs) are pacemaker cells of the GI tract. In this study, the authors investigated the effects of NRG on ICCs and on GI motility in vitro and in vivo.

Methods: ICCs were dissociated from mouse small intestines by enzymatic digestion. The whole-cell patch clamp configuration was used to record pacemaker potentials in cultured ICC clusters. The effects of NRG on GI motility were investigated by calculating percent intestinal transit rates (ITR) using Evans blue in normal mice.

Results: NRG inhibited ICC pacemaker potentials in a dose-dependent manner. In the presence of tetraethylammonium chloride or iberiotoxin, NRG had no effect on pacemaker potentials, but it continued to block pacemaker potentials in the presence of glibenclamide. Preincubation with SQ-22536 had no effect on pacemaker potentials or on their inhibition by NRG. However, 1H-[1,2,4]oxadiazo[4,3-a]quinoxalin-1-one blocked pacemaker potential inhibition by NRG. In addition, L-NG-nitroarginine methyl ester blocked pacemaker potential inhibition by NRG. Furthermore, NRG significantly suppressed murine ITR enhancement by neostigmine in vivo.

Conclusion: This study shows NRG dose-dependently inhibits ICC pacemaker potentials via a cyclic guanosine monophosphate/nitric oxide-dependent pathway and Ca²⁺-activated K⁺ channels in vitro. In addition, NRG suppressed neostigmine enhancement of ITR in vivo.

© 2017 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Division of Longevity and Biofunctional Medicine, Pusan National University School of Korean Medicine, Yangsan 50612, Republic of Korea.

E-mail address: vision@pusan.ac.kr (B.J. Kim).
http://dx.doi.org/10.1016/j.imr.2017.02.001
2213-4220 © 2017 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Natural products derived from foods and traditional herbs have been traditionally used to treat infections, inflammatory and gastrointestinal (GI) diseases, and other disease types. Naringenin [NRG; 5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one] is a type of natural flavonoid, and is found in grapefruit, bitter orange, and other fruits. NRG has wide range of biological and pharmacological activities, which include anti-inflammatory, antiinflammatory, antiatherogenic, antioxidant, and anticancer effects, and has a relaxant effect on vascular smooth muscle and a regulatory effect on GI function. Interstitial cells of Cajal (ICCs) are the pacemaker cells of GI muscularis propria, and are involved in the generation of primary electrical pacemaker activity, which controls GI motility. These cells also form a bridge between enteric motor nerve terminals and smooth muscle cells. Because of the central role played by ICCs in GI motility, loss of these cells is extremely detrimental to GI functions.

As the effects of NRG on ICCs and GI motility have not been previously investigated, we undertook to investigate its effects on the pacemaker potentials of clusters of murine small intestine ICCs in vitro and on GI motor functions in vivo by measuring intestinal transit rates (ITRs) in Evans blue in mice.

2. Methods

2.1. Ethics

Animal care and experiments were conducted in accordance with the guidelines issued by the ethics committee of Pusan National University (Busan, Korea; Approval no. PNU-2016-1370) and those issued by the National Institute of Health ‘Guide for the Care and Use of Laboratory Animals’ (2013).

2.2. Preparation of cells and cell cultures

BALB/c mice (aged 2–6 days; weight, 2.1–2.3 g; Samtako Bio Korea Co., Ltd., Osan, Korea) were anesthetized with 0.1% ether (Sigma–Aldrich, St Louis, MO, USA; Merck Millipore, Darmstadt, Germany) and sacrificed by cervical dislocation. Mice were maintained under controlled conditions (21 ± 2 °C, relative humidity 50 ± 5%; 12-h light/dark cycle) and allowed free access to food and water. Small intestines were removed and opened along the mesenteric border, and luminal contents were removed by washing with Krebs–Ringer bicarbonate solution. Small intestine mucosa were removed by sharp dissection and small strips of intestine muscle were equilibrated in Ca²⁺-free physiological salt solution (125 mM NaCl, 5.36 mM KCl, 0.34 mM NaOH, 0.44 mM Na₂HCO₃, 10 mM glucose, 2.9 mM succrose, and 11 mM HEPES buffer) for 20 min and then dispersed using an enzyme solution containing 1.5 mg/mL collagenase (Worthington Biochemical Corp., Lakewood, NJ, USA), 2.5 mg/mL bovine serum albumin (Sigma–Aldrich; Merck Millipore), 2.5 mg/mL trypsin inhibitor (Sigma–Aldrich; Merck Millipore), and 0.5 mg/mL adenosine triphosphate (ATP; Sigma–Aldrich; Merck Millipore). Cells were plated on glass coverslips coated with 0.01% poly-L-lysine solution (Sigma–Aldrich; Merck Millipore) and cultured in a 95% O₂/5% CO₂ atmosphere in smooth muscle basal medium (Clontech Corp.; Lonza, Walkersville, MA, USA) supplemented with stem cell factor (5 ng/mL; Sigma–Aldrich; Merck Millipore) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37 °C.

2.3. Patch-clamp experiments

The cells were transferred onto a solution chamber on the stage of an inverted microscope (IX70; Olympus, Tokyo, Japan). The whole-cell patch-clamp technique was used to record the membrane potentials (current clamp) of cultured ICCs as described previously and an Axopatch 200 B amplifier (Axon Instruments, Foster City, CA, USA) was used to amplify membrane potentials. Bath solution (Normal Tyrode) contained 135 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM glucose, and 10 mM HEPES with a pH that was adjusted to 7.4 using NaOH. The internal solution contained 145 mM Cs-glutamate, 8 mM NaCl, 10 mM BAPTA, and 10 mM HEPES-CsOH, with pH adjusted to 7.2 with CsOH. All experiments were performed at 30 °C.

2.4. In vivo intestine motility measurements

Mice were randomly allocated into four groups: the normal group (saline controls); neostigmine (0.2 mg/kg) group; neostigmine and low-dose naringenin (10 mg/kg) group; and the neostigmine and high-dose naringenin (20 mg/kg) group. Animals were fasted for 12 h prior to the intraperitoneal administration of drugs or saline solution. Immediately after treatment, 0.5 mL of Evans blue was administered by gavage. Mice were sacrificed 30 min after Evans blue administration and entire intestines (from pylorus to the anus (anal ring)) were excised. Total intestinal lengths and distances traveled by Evans blue were then measured. Intestine transit rate (ITR) was defined as the distance traveled by Evans blue expressed as a percentage of total intestinal length, as described elsewhere.

2.5. Drugs

Drugs were purchased from Sigma–Aldrich. To produce stock solutions, all drugs were dissolved in distilled water or dimethylsulfoxide (DMSO) and stored at –20 °C. The final concentration of DMSO in bath solution was always <0.1%, and at this level DMSO did not affect the results.

2.6. Statistics

Results are expressed as mean ± standard error. The analysis was performed using the Student t test or by analysis of variance (ANOVA) followed by Tukey’s multiple comparison test, as appropriate, using GraphPad Prism version 6. Statistical significance was accepted for p values <0.05. The n values reported in the text refer to the number of cells used in patch-clamp experiments.
3. Results

3.1. Effects of NRG on ICC pacemaker potentials

Spontaneous pacemaker potentials (PPs) were generated by cultured ICCs in current clamp mode (i = 0). Under current clamp conditions, NRG (100–300 µM) inhibited spontaneous PPs (Fig. 1A–C). The mean amplitude or frequency of ICC PPs in the absence of NRG was 23.5 ± 1.7 mV or 9.8 ± 0.9 cycles/min (n = 8), but after treatment with NRG, mean PP amplitude or frequency changed to 11.2 ± 0.9 mV or 9.2 ± 0.5 cycles/min at 100 µM, 7.5 ± 0.7 mV or 10.1 ± 0.8 cycles/min at 200 µM, and 1.6 ± 0.8 mV or 0.5 ± 0.6 cycles/min at 300 µM (n = 7–9, Fig. 1D, E). These results suggest that NRG dose-dependently inhibits ICC PPs.

3.2. The effect of potassium channel blockers on PP inhibition by NRG

Various types of potassium channel blockers were used to identify the potassium channels responsible for NRG-induced PP inhibition. Treatment of ICC with 1 mM tetroethylammonium chloride (TEA, a Ca<sup>2+</sup>-activated K<sup>+</sup> channel blocker) or iberiotoxin (100 µM) had no effect on the pacemaker activities of treatment naïve ICCs. In the presence of TEA or iberiotoxin, NRG had no effects on PPs (n = 5; Fig. 2B, C). Furthermore, glibenclamide (10 µM; an ATP-sensitive K<sup>+</sup> channel blocker), did not affect the PPs of treatment naïve ICCs or PP inhibition by NRG (n = 6, Fig. 2D). In the presence of NRG, PP amplitudes and frequency were: 22.3 ± 1.1 mV and 10.1 ± 0.8 cycles/min for TEA; 22.3 ± 1.0 mV and 9.6 ± 0.8 cycles/min for iberiotoxin; and 1.5 ± 0.6 mV and 0.3 ± 0.5 cycles/min for glibenclamide (n = 6–8; Fig. 2E, F). These results suggest that NRG activates Ca<sup>2+</sup>-activated K<sup>+</sup> channel in ICCs.

3.3. Involvements of guanylate cyclase and nitric oxide in pacemaker potential inhibition by NRG

To determine whether PP inhibition by NRG is mediated by a cyclic nucleotide-dependent pathway, we investigated the effects of pretreating ICCs with SQ-22536 (a adenylate cyclase inhibitor) or 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (a guanylate cyclase inhibitor; ODQ). Preincubation with SQ-22536 (10 µM) for 10 min had no effect on PPs, and in the presence of SQ-22536, NRG (300 µM) inhibited PPs (Fig. 3B). However, ODQ (10 µM) blocked PP inhibition by NRG (Fig. 3C). Because nitric oxide (NO) activates soluble guanylyl cyclase, and thus results in the formation of cyclic guanosine monophosphate (cGMP),<sup>18</sup> we treated ICCs with LNAME (10 µM; L-NG-nitroarginine methyl ester, a nonselective NO synthase inhibitor) to determine whether PP inhibition by NRG was mediated by NO. It was found that L-NAME blocked PP inhibition by NRG (Fig. 3D). Also, to confirm the involvement of NO, we applied NO donor, sodium nitroprusside (SNP) in PP. It was found SNP inhibited ICC PPs (Fig. 3E). In the presence of NRG, PP amplitudes or frequency were 1.3 ± 0.5 mV or 0.5 ± 0.6 cycles/min for SQ-22536, 22.1 ± 1.3 mV or 9.3 ± 0.5 cycles/min for ODQ, and 22.1 ± 1.2 mV or 9.8 ± 0.6 cycles/min for L-NAME (n = 5–7; Fig. 3F, G). These results suggest that cGMP and NO participate in PP inhibition by NRG.
Accordingly, and ICCs

Thus, furthermore, and µM

NRG

Thus, 3.4.

NRG inhibited neostigmine-induced intestinal hyperactivity

The observed inhibitory effect of NRG on the PP amplitudes of ICCs in vitro led us to examine the effect of NRG on ITRs in vivo. Previous studies have demonstrated neostigmine increases intestinal motor activity, colonic contractility, and ITTs in man.19,20 In neostigmine-administered mice, application of 10 mg/kg or 20 mg/kg NRG significantly reduced neostigmine-induced ITR enhancement (Fig. 4).

4. Discussion

In this study, we investigated the effect of NRG on GI motility by examining its influence on the pacemaker activities of ICCs of the murine small intestine in vitro and on intestinal transit rates in vivo. NRG inhibited ICC PPs via Ca²⁺-sensitive K⁺ channel and a cGMP/NO-dependent pathway, which suggests that NRG might have potential use for the regulation of GI motility.

Flavonoids are important natural compounds as they possess diverse biologic activities. NRG is a well-known flavonoid and a member of the flavanones. It is particularly abundant in citrus fruits, especially the grapefruit.21 NRG has been shown to have therapeutic effects in various diseases, such as, metabolic syndrome.22 Furthermore, NRG affects the GI tract, and has relaxing effects on contractility of vascular smooth muscle9 and inhibits rat and rabbit colon smooth muscle contraction.23,24 NRG has also been reported to reduce gastric tone25 and intestinal peristalsis,26 to alter gut microecology, and have positive effects on gut health.27 Accordingly, it was suggested that NRG might be a useful dietary adjunct for the treatment of various human ailments.28

GI diseases importantly affect quality of life. However, the management of GI disorders is now problematic as several drugs, like cisapride and tegaserod (both now withdrawn), that ameliorate symptoms have significant adverse events.29,30 In complementary and alternative medicine, herbal products are usually used to treat GI disorders. In fact, up to 40% of patients with irritable bowel syndrome were found to be taking some form of herbal medication.31,32 ICCs act as pacemaker cells of the gastrointestinal tract and control GI motility12–14 and many GI motility disorders, such as achalasia of cardia, slow transit constipation, and inflammatory bowel disease, have been associated with ICC abnormalities.33 Thus, understanding of the mechanisms underlying pacemaker activity and ICC excitability is of crucial importance.
Fig. 3 – The effects of SQ-22536 (an adenylate cyclase inhibitor), ODQ (a guanylate cyclase inhibitor), and L-NAME (a nonselective nitric oxide synthase inhibitor) on pacemaker potential (PP) inhibition by NRG in cultured ICCs. (A) Pacemaker activities of interstitial cells of Cajal exposed to NRG (300 µM) in current-clamp mode (I = 0). (B) Pacemaker activities of a single interstitial cell of Cajal exposed to NRG in the presence of SQ-22536 (10 µM). SQ-22536 had no effect on PP inhibition by NRG. Pacemaker activities of ICCs exposed to NRG in the presence of (C) ODQ (10 µM), or (D) L-NAME (10 µM). Both inhibitors blocked PP inhibition by NRG. (E) NO donor, SNP inhibited ICC PPs. (F,G) The graph summarizes responses to NRG in the presence of SQ-22536, ODQ, or L-NAME. Bars represent mean ± standard error. ***p < 0.001. CTRL, control; NRG, naringenin; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinazolin-1-one; L-NAME, L-NG-nitroarginine methyl ester; n.s., not significant.

Fig. 4 – The effect of NRG on neostigmine-administered mice in vivo. NRG at 10 mg/kg or 20 mg/kg inhibited intestinal transit rate increases evoked by neostigmine. Bars represent mean ± standard error. ***p < 0.001. NRG, naringenin.
In the present study, we examined for the first time, the effects of NRG on the PPs of ICCs of the murine small intestine. These PPs primarily occur because of periodic activations of TRPM7 or ANO1 channels. However, in the case of NRG, it has not been determined which ion channels regulate PPs. In the present study, NRG was found to activate Ca2+-activated K+ channel in ICCs (Fig. 2). These channels are broadly expressed in GI smooth muscle cells, and play a key role in controlling the excitability of smooth muscle cells. Also, in ICC, the presence of Ca2+-activated K+ channels in single ICC was found in guinea pig and many other K+ channels were involved in regulation of PPs in ICC. Voltage gated K+ 1.1 channels, small-conductance Ca2+-activated K+ channels, Ether-à-go-go-related gene K+ channels are expressed in ICCs and may play an important role in generating a rhythmic pacemaker current in the GI tract.

Taken together, we found NRG reduced the amplitudes of the PPs of ICCs in a cGMP/NO-dependent manner by activating Ca2+-sensitive K+ channel. Furthermore, NRG inhibited neostigmine enhancement of ITR in vivo.

**Conflicts of interest**

The authors have no conflict of interest.

**Acknowledgments**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant no. NRF-2014R1A1A2054469).

**References**

1. Koebeler A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today 2014;19:1871–82.

2. Liu X, Wang N, Fan S, Zheng X, Yang Y, Zhu Y, et al. The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway. Sci Rep 2016;6:39735.

3. Ling W, Li Y, Jianguo W, Sui Y, Zhao HL. Common mechanism of pathogenesis in gastrointestinal diseases implied by consistent efficacy of single Chinese medicine formula: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2015;94:e111.

4. Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY, Yin MC. Anti-inflammatory and anti-bacterial effects of naringenin in diabetic mice. J Agric Food Chem 2012;60:514–21.

5. Shi Y, Dai J, Liu H, Li RR, Sun PL, Du Q, et al. Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-kappaB activity in a murine model of asthma. Can J Physiol Pharmacol 2009;87:729–35.

6. Lee S, Lee CH, Moon SS, Kim E, Kim CT, Kim BH, et al. Naringenin derivatives as anti-atherogenic agents. Bioorg Med Chem Lett 2003;13:3901–3.

7. Meraibah SD, Dassprakash MV, Saraswathy SD. Protective effect of naringenin on hepatic and renal dysfunction and oxidative stress in arsenic intoxicated rats. Mol Biol Rep 2013;40:3681–91.

8. Abaza MS, Orabky KY, Al-Quattan E, Al-Attiyah RJ. Growth inhibitory and chemo-sensitization effects of naringenin, a natural flavanone purified from Thymus vulgaris, on human breast and colorectal cancer. Cancer Cell Int 2015;15:46.

9. Ajay M, Gilani AU, Mustafa MR. Effects of flavonoids on vascular smooth muscle of the isolated rat thoracic aorta. Life Sciences 2003;74:603–12.

10. Yang Z, Pan A, Zuo W, Guo J, Zhou W. Relaxant effect of flavonoid naringenin on contractile activity of rat colonic smooth muscle. J Ethnopharmacol 2014;155:1177–83.

11. Choudhury R, Chowrimootoo G, Srai K, Debnam E, Rice-Evans CA. Interactions of the flavonoid naringenin in the gastrointestinal tract and the influence of glycosylation. Biochem Biophys Res Commun 1999;265:410–5.

12. Sanders KM, Ward SM, Koh SD. Intestinal cells: regulators of smooth muscle function. Physiol Rev 2014;94:859–907.

13. Blair PJ, Rhee PL, Sanders KM, Ward SM. The significance of interstitial cells in neurogastroenterology. J Neurogastroenterol Motil 2014;20:294–317.

14. Kim BJ, Lee GS, Kim HW. Involvement of transient receptor potential melastatin type 7 channels on Porcine fructus-induced depolarizations of pacemaking activity in interstitial cells of Cajal from murine small intestine. Integr Med Res 2013;2:62–9.

15. Al-Shoul O. The importance of interstitial cells of Cajal in the gastrointestinal tract. Saudi J Gastroenterol 2013;19:3–15.

16. Kim HJ, Park SY, Kim DC, Park SH, Lee H, Hwang DY, et al. Effects of the roots of Liriope Platypylla Wang Et tang on gastrointestinal motility function. J Ethnopharmacol 2016;184:144–53.

17. Lee MC, Ha W, Park J, Kim J, Jung Y, Kim BJ. Effects of Lizhong Tang on gastrointestinal motility in mice. World J Gastroenterol 2016;22:7778–86.

18. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–142.

19. Corsetti M, Gevers AM, Caenepeel P, Tack J. The role of tension receptors in colonic mechanosensitivity in humans. Gut 2004;53:1787–93.

20. Law NM, Bharucha AE, Undale AS, Zinsmeister AR. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G1228–37.

21. Orhan IE, Nabavi SF, Daglia M, Tenore GC, Mansouri K, Nabavi SM. Naringenin and atherosclerosis: a review of literature. Curr Pharm Biotechnol 2015;16:245–51.

22. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 2014;5:404–17.

23. Zhang QR, Zhu KG, Peng JX, Li L. Effect of Zhishi decoction on isolated rabbit colon smooth muscle activity. Chin J Trad Med Sci Technol 2006;3:279–80.

24. Liu Y, Feng YE, Wang R, Qiu GQ, Cai Y, Sun Y. Effect of Zhishi and drug contained serum on isolated STC rat colon smooth muscle activity. J Beijing Univ Trad Chin Med 2010;33:402–5.

25. Hammad HM, Abdalla SS. Pharmacological effects of selected flavonoids on rat isolated ileum: structure-activity relationship. Gen Pharmacol 1997;28:767–71.

26. Gharzouli H, Holzer P. Inhibition of guinea pig intestinal peristalsis by the flavonoids quercetin, naringenin, apigenin and genistein. Pharmacology 2004;70:5–14.

27. Parkar SG, Stevenson DE, Skinner MA. The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol 2008;124:295–8.

28. Suramalli G, Nanjwade BK, Patil PA. Safety evaluation of naringenin upon experimental exposure on rat
gastrointestinal epithelium for novel optimal drug delivery. Drug Deliv 2016;23:512–24.
29. Glessner MR, Heller DA. Changes in related drug class utilization after market withdrawal of cisapride. Am J Manag Care 2002;8:243–50.
30. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007;132:2287–90.
31. Rawsthorne P, Shanahan F, Cronin NC, Anton PA, Löfberg R, Bohman L, et al. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:1298–303.
32. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001;34:595–603.
33. Vanderwinden JM, Rumessen JJ. Interstitial cells of Cajal in human gut and gastrointestinal disease. Microsc Res Tech 1999;47:344–60.
34. Kim BJ, Hong C. Role of transient receptor potential melastatin type 7 channel in gastric cancer. Integr Med Res 2016;5:124–30.
35. Gim H, Nam JH, Lee S, Shim JH, Kim HJ, Ha KT, et al. Quercetin inhibits pacemaker potentials via nitric oxide/cGMP-dependent activation and TRPM7/ANO1 channels in cultured interstitial cells of Cajal from mouse small intestine. Cell Physiol Biochem 2015;35:2422–36.
36. Benham CD, Bolton TB, Lang RJ, Takewaki T. The mechanism of action of Ba²⁺ and TEA on single Ca²⁺-activated K⁺ channels in arterial and intestinal smooth muscle cell membranes. Pflügers Arch 1985;403:120–7.
37. Carl A, Sanders KM. Ca²⁺-activated K⁺ channels of canine colonic myocytes. Am J Physiol 1989;257:C470–80.
38. McManus OB. Calcium-activated potassium channels: regulation by calcium. J Bioenerg Biomembr 1991;23:537–60.
39. Lawson K. Potassium channel activation: a potential therapeutic approach? Pharmacol Ther 1996;70:39–63.
40. Kim YC, Suzuki H, Xu WX, Choi W, Kim SH, Lee SJ. Ca²⁺-activated K⁺ current in freshly isolated c-Kit positive cells in guinea-pig stomach. J Korean Med Sci 2009;24:384–91.
41. Lang RJ, Tonta MA, Takano H, Hashitani H. Voltage-operated Ca²⁺ currents and Ca²⁺-activated Cl⁻ currents in single interstitial cells of the guinea-pig prostate. BJU Int 2014;114:436–46.
42. Hatton WJ, Mason HS, Carl A, Doherty P, Latten MJ, Kenyon JL, et al. Functional and molecular expression of a voltage-dependent K⁺ channel (Kv1.1) in interstitial cells of Cajal. J Physiol 2001;533:315–27.
43. Fujita A, Takeuchi T, Saitoh N, Hanai J, Hata F. Expression of Ca²⁺-activated K⁺ channels, SK3, in the interstitial cells of Cajal in the gastrointestinal tract. Am J Physiol Cell Physiol 2001;281:C1727–33.
44. Zhu Y, Golden CM, Ye J, Wang XY, Akbarali HI, Huizinga JD. ERG K⁺ currents regulate pacemaker activity in ICC. Am J Physiol Gastrointest Liver Physiol 2003;285:G1249–58.